HOLOGIC Business Summary

Hologic Inc. (HOLX) is a premier medical technology innovator specializing in women’s health, utilizing a business model that integrates high-value capital equipment placements with a high-margin recurring revenue stream from consumables, molecular assays, and service contracts. The company’s operations are organized into four primary segments: Diagnostics (44% of revenue), which centers on the Panther molecular testing platform and cytology solutions; Breast Health (38%), led by its Genius 3D Mammography systems and interventional biopsy tools; GYN Surgical (16%), featuring the MyoSure and Fluent tissue removal systems; and Skeletal Health (2%). Hologic maintains a dominant market position in breast cancer screening and cervical health diagnostics, competing directly with diversified medtech giants such as Roche, Becton Dickinson (BD), GE HealthCare, and Boston Scientific by leveraging its proprietary "Science of Sure" clinical precision. The company is led by Chairman, President, and CEO Stephen P. MacMillan, a veteran executive who previously served as CEO of Stryker Corporation and held senior roles at Johnson & Johnson and Procter & Gamble. The executive leadership team includes CFO Karleen Oberton and COO Essex Mitchell, both of whom have been instrumental in the company’s operational scaling and recent strategic acquisitions, such as Endomagnetics and Gynesonics. Founded in 1985 by Dr. Jay A. Stein, who continues to serve as Chairman Emeritus and a technical advisor, Hologic is currently transitioning through a landmark $18 billion take-private acquisition by Blackstone and TPG, a transaction approved by shareholders in February 2026. The company’s board of directors features notable industry figures, including Lead Independent Director Amy Wendell and Wayde McMillan, the CFO of Solventum.